To investigate outcomes, including survival and progression-free status, of patients with relapsed/refractory multiple myeloma who discontinued bispecific antibody therapy for reasons other than disease progression or death.
Key Findings:
82.6% of patients remained alive and progression-free at a median follow-up of 15.5 months post-bsAb discontinuation.
Estimated Progression-Free Survival (PFS) at 6, 12, and 18 months was 90.5%, 84.0%, and 70.0%, respectively.
The most common reasons for treatment discontinuation were infections (n=12) and second malignancies (n=2).
All patients with sustained responses maintained or improved their response depth at latest follow-up.
Interpretation:
The study suggests that fixed-duration bispecific antibody therapy may lead to sustained remission in heavily pre-treated patients with relapsed/refractory multiple myeloma, indicating a significant proportion remain progression-free after treatment discontinuation, which may influence future treatment strategies.
Limitations:
The study is retrospective and lacks prospective data on response durability with fixed-duration dosing, which may limit the reliability of the findings.
The small sample size may limit the generalizability of the findings to the broader patient population.
Conclusion:
Over 80% of patients with relapsed/refractory multiple myeloma who discontinued bispecific antibody therapy for reasons other than progression or death remained in sustained remission at 1 year, highlighting the potential of fixed-duration therapy in this patient population.
